Page last updated: 2024-12-05

2,5-hexanedione

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

2,5-hexanedione: metabolite of methyl-n-butyl ketone [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

2,5-hexanedione : A diketone that is hexane substituted by oxo groups at positions 2 and 5. It is a toxic metabolite of hexane and of 2-hexanone [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID8035
CHEMBL ID1564795
CHEBI ID85014
SCHEMBL ID10001
MeSH IDM0057431

Synonyms (72)

Synonym
nsc7621
acetonyl acetone
.alpha.,.beta.-diacetylethane
wln: 1v2v1
2,5-diketohexane
acetone, acetonyl-
nsc-7621
2,5-hexadione
diacetonyl
1,2-diacetylethane
110-13-4
2,5-hexanedione
2,5-dioxohexane
hexanedione, 2,5-
acetonylacetone
hexane-2,5-dione
inchi=1/c6h10o2/c1-5(7)3-4-6(2)8/h3-4h2,1-2h
NCGC00091466-01
smr000568468
MLS001065580 ,
einecs 203-738-3
ccris 2919
2,5-hexandione
alpha,beta-diacetylethane
nsc 7621
ai3-02399
brn 0506525
2,5-hexanedione, >=98%
H0101
AKOS000119007
A802149
NCGC00091466-02
c0z8884j3p ,
unii-c0z8884j3p
4-01-00-03688 (beilstein handbook reference)
LMFA12000081
tox21_200618
dtxcid6010138
NCGC00258172-01
cas-110-13-4
dtxsid8030138 ,
FT-0621812
acan
acetonylacetone [mi]
BBL027731
SCHEMBL10001
cid_8035
bdbm73981
hexan-2,5-dione
hexan-2,5-dion
acetonylaceton
2,5-hexane-di-one
chebi:85014 ,
CHEMBL1564795
Q-200202
ch3coch2ch2coch3
hexanedione-(2,5)
mfcd00008792
acetonylacetone/2,5-diketohexane
2,5-hexanedione, 97%
F0001-0216
GS-3782
2,5-hexanedione, analytical standard
2,5-hexanedione, puriss. p.a., >=99.0%
D71099
EN300-19144
2,5-hexanedione, vetec(tm) reagent grade, 98%
CS-D1203
Q209264
AMY25528
STL194267
hexan-2

Research Excerpts

Toxicity

Chronic exposure to n-hexane causes sensorimotor neuropathy. Neuropathy is mainly mediated by its toxic metabolite, 2,5-hexanedione (HD) NAC protects against 2, 5-HD neurotoxicity and DMPN may be proposed as a new sensitive and specific biomarker.

ExcerptReferenceRelevance
" This dose approximates the single dose LD50 (2."( Further studies on ketone neurotoxicity and interactions.
DiVincenzo, GD; Katz, GV; Krasavage, WJ; O'Donoghue, JL, 1984
)
0.27
" These observations support the hypothesis that covalent crosslinking of the stable neurofilament is the primary event in the molecular pathogenesis of these toxic neuropathies, and that the rate of crosslinking of neurofilaments determines the proximodistal location of the axonal swelling."( The effect of 3,4-dimethyl substitution on the neurotoxicity of 2,5-hexanedione. I. Accelerated clinical neuropathy is accompanied by more proximal axonal swellings.
Anthony, DC; Boekelheide, K; Graham, DG, 1983
)
0.5
" In addition, chloroform was significantly more toxic than deutero-chloroform in hepatocytes from either corn oil- or HD-pretreated rats."( Potentiation of chlorinated hydrocarbon toxicity by 2,5-hexanedione in primary cultures of adult rat hepatocytes.
Harbison, RD; Jernigan, JD; Pounds, JG,
)
0.38
"The protective role of zinc against the toxic effects of 2, 5-hexanedione (2,5-HD), the main neurotoxic metabolite of n-hexane, was investigated by studying the interference of zinc on the toxicokinetics of 2,5-HD."( Evidence for zinc protection against 2,5-hexanedione toxicity by co-exposure of rats to zinc chloride.
Batoreu, MC; Mateus, ML; Santos, AP,
)
0.4
" These alpha-diketones also display a degree of toxic selectivity towards neuroblastoma cells, which may have therapeutic implications."( A comparison of the apoptotic and cytotoxic effects of hexanedione derivatives on human non-neuronal lines and the neuroblastoma line SH-SY5Y.
Coleman, MD; Griffiths, HR; Woehrling, EK; Zilz, TR, 2008
)
0.35
" The toxic effect of this compound was similar in control cells irrespective of the mtDNA background."( The background of mitochondrial DNA haplogroup J increases the sensitivity of Leber's hereditary optic neuropathy cells to 2,5-hexanedione toxicity.
Achilli, A; Barbieri, A; Carelli, V; Ghelli, A; Iommarini, L; Mattioli, S; Pala, M; Porcelli, AM; Rugolo, M; Torroni, A; Vidoni, S; Zanna, C, 2009
)
0.56
" Taken together, our findings suggest that at the studied conditions NAC protects against 2,5-HD neurotoxicity and DMPN may be proposed as a new sensitive and specific biomarker of 2,5-HD neurotoxicity in animals treated with a toxic amount of 2,5-hexanedione."( Role of N-acetylcysteine in protecting against 2,5-hexanedione neurotoxicity in a rat model: changes in urinary pyrroles levels and motor activity performance.
Andrade, V; Batoréu, MC; dos Santos, AP; Gonçalves, LL; Mateus, ML; Torres, ME, 2014
)
0.84
"Chronic exposure to n-hexane, a widely used solvent in industry, causes sensorimotor neuropathy, which is mainly mediated by its toxic metabolite, 2,5-hexanedione (HD)."( Glibenclamide attenuates 2,5-hexanedione-induced neurotoxicity in the spinal cord of rats through mitigation of NLRP3 inflammasome activation, neuroinflammation and oxidative stress.
Hou, L; Huang, R; Li, S; Wang, Q; Yang, J; Zhang, D; Zhao, J, 2020
)
1.06
"Currently, whether nod-like receptor family pyrin domain-containing 3 (NLRP3) inflammasome activation contributes to neuropathy induced by 2,5-Hexanedione (HD), the toxic metabolite of n-hexane, remains unknown."( NLRP3 inflammasome mediates 2,5-hexanedione-induced neurotoxicity through regulation of macrophage infiltration in rats.
Hou, L; Huang, R; Ruan, Z; Sun, W; Wang, Q; Zhang, D, 2020
)
1.05
"Chronic exposure to n-hexane causes sensorimotor neuropathy, which is mediated by 2,5-hexanedione (HD), a toxic metabolite of n-hexane."( 2,5-hexanedione induces NLRP3 inflammasome activation and neurotoxicity through NADPH oxidase-dependent pathway.
Hou, L; Huang, R; Ruan, Z; Sun, W; Wang, Q; Zhai, X; Zhang, D; Zhao, X, 2021
)
2.29

Pharmacokinetics

ExcerptReferenceRelevance
"Biological exposure index (BEI) of n-hexane was studied for accuracy using a physiologically based pharmacokinetic (PB-PK) model."( "Dynamic" biological exposure indexes for n-hexane and 2,5-hexanedione, suggested by a physiologically based pharmacokinetic model.
Brugnone, F; Mozzo, P; Olivato, D; Perbellini, L, 1990
)
0.53
" 2,5-HD disappeared monoexponentially from the application site with a half-life of 6 hr."( Disposition, pharmacokinetics, and metabolism of a dermal dose of [14C]2,5-hexanedione in hens.
Abou-Donia, MB; Nomeir, AA; Suwita, E,
)
0.36
" Many pharmacokinetic processes such as metabolism and absorption can be impacted by the presence of other chemicals in the environment and diet and as a result of medication."( Pharmacokinetics, chemical interactions, and toxicological risk assessment in perspective.
Blancato, JN, 1994
)
0.29

Compound-Compound Interactions

ExcerptReferenceRelevance
"This investigation was designed to study the neurotoxicity produced in hens by the aliphatic hexacarbons n-hexane, methyl n-butyl ketone (MnBK), 2,5-hexanediol (2,5-HDOH), and 2,5-hexanedione (2,5-HD) following daily dermal application of each chemical alone and in combination with O-ethyl O-4-nitrophenyl phenylphosphonothioate (EPN)."( Pattern of neurotoxicity of n-hexane, methyl n-butyl ketone, 2,5-hexanediol, and 2,5-hexanedione alone and in combination with O-ethyl O-4-nitrophenyl phenylphosphonothioate in hens.
Abou-Donia, MB; Campbell, GM; Makkawy, HM, 1985
)
0.69

Dosage Studied

Rats were dosed with 2,5-hexanedione (2, 5-HD), acetone, ethanol or combinations of these for 6 weeks. Deaths occurred in all groups of hens given 2,4- Hexanedione before sacrifice at 3 wk. All rats given 2,.5- hexanedione survived a 4-wk study period.

ExcerptRelevanceReference
" Therefore, both ACR and 2,5-HD produce a transient and repeated compromise of fast anterograde transport during the dosing regimen which results in distal nerve degeneration."( Toxic neurofilamentous axonopathies and fast anterograde axonal transport. III. Recovery from single injections and multiple dosing effects of acrylamide and 2,5-hexanedione.
Sickles, DW, 1991
)
0.48
" Anatomical findings indicate damage to one type of retinal ganglion cell, the large (alpha) or Y-cell class, both during dosing and after a long recovery period."( Selective damage to large cells in the cat retinogeniculate pathway by 2,5-hexanedione.
Eskin, TA; Flood, DG; Merigan, WH; Pasternak, T, 1985
)
0.5
" The exact location at which axonal enlargements occur appears to be a continuous function, dependent on both the structure and dosage schedule of the chemical toxin."( Pathogenesis of experimental giant neurofilamentous axonopathies: a unified hypothesis based on chemical modification of neurofilaments.
Autilio-Gambetti, L; Gambetti, P; Sayre, LM, 1985
)
0.27
"Rats were dosed with 2,5-hexanedione (2,5-HD), acetone, ethanol or combinations of these for 6 weeks."( Neurophysiological and behavioural effects of combined exposure to 2,5-hexanedione and acetone or ethanol in rats.
Hass, U; Ladefoged, O; Simonsen, L, 1989
)
0.83
" Both the extent of this crosslinking and its localization in particular portions of peripheral nerves showed a correlation with HD dosage and with the known progression of ultrastructural features during HD-induced neuropathy."( 2,5-Hexanedione neuropathy is associated with the covalent crosslinking of neurofilament proteins.
Carden, MJ; Lee, VM; Schlaepfer, WW, 1986
)
1.71
" Simultaneous dosing with acetone altered the toxicokinetic model which best described the plasma concentration versus time data."( Acetone-induced changes in the toxicokinetics of 2,5-hexanedione in rabbits.
Ladefoged, O; Perbellini, L, 1986
)
0.53
" Cessation of dosing resulted in some recovery from clinical neuropathy but virtually no change in histopathologically demonstrable CNS damage."( Alterations in rat axonal cytoskeletal proteins induced by in vitro and in vivo 2,5-hexanedione exposure.
DeCaprio, AP; O'Neill, EA, 1985
)
0.5
" Baseline data were collected before dosing started."( Assessment of the effects of acrylamide, methylmercury, and 2,5-hexanedione on motor functions in mice.
Gilbert, SG; Maurissen, JP, 1982
)
0.51
" Onset of behavioral deficits appeared after four dosage weeks."( A neurobehavioral model of 2,5-hexanedione-induced neuropathy.
Sheppard, RC; Sterman, AB,
)
0.43
" High pressure liquid chromatography (HPLC) permitted the detection of the dicarboxylic acids malonic acid and glutaric acid in the n-nonane dosed rat urines."( The metabolism of n-nonane in male Fischer 344 rats.
Baughman, TM; Bombick, DD; Jarnot, BM; Ketcha, M; Mattie, DR; Serve, MP, 1995
)
0.29
" Animals were intoxicated with 2,5-hexanedione by two dosing paradigms: intraperitoneal or oral."( 2,5-Hexanedione alters elemental composition and water content of rat peripheral nerve myelinated axons.
Hussein, SJ; Lehning, EJ; LoPachin, RM; Saubermann, AJ; Stack, EC, 1994
)
2.02
" Deaths occurred in all groups of hens given 2,5-hexanedione (75, 105, or 150 mg/kg) before sacrifice at 3 wk, but all rats given 2,5-hexanedione (150, 225, 350 mg/kg) survived a 4-wk study period, even though gait changes were evident in the 225 and 350 mg/kg dosage groups by 3 wk."( Comparison of toxicities of acrylamide and 2,5-hexanedione in hens and rats on 3-week dosing regimens.
Ehrich, M; Jortner, BS, 1993
)
0.81
" We employed two differently designed experiments with respect to the dosage levels and treatment periods for developing clinical neuropathies."( The effects of 2,5-hexanedione and acrylamide on myosin heavy chain isoforms of slow and fast skeletal muscles of the rat.
Futatsuka, M; Miyamoto, E; Nagano, M; Oishi, Y; Yamamoto, H, 1996
)
0.65
" vs gavage) of intoxication have shown that swelling and degeneration were related to neurotoxicant dosing conditions (i."( Redefining toxic distal axonopathies.
LoPachin, RM, 2000
)
0.31
" HD was administered by gavage according to different daily dosing regiments (100, 175, 250, or 400 mg/kg/day) and four proximodistal nerve regions (5th lumbar spinal nerve, proximal and distal sciatic nerve, and tibial nerve) were examined morphometrically."( gamma-diketone peripheral neuropathy. I. Quality morphometric analyses of axonal atrophy and swelling.
Arezzo, JC; Fox, JH; Jortner, BS; Kitano, T; Lehning, EJ; LoPachin, RM, 2000
)
0.31
" Therefore, as a possible mechanism of atrophy, NF subunit (NF-L, -M, and -H) proteins were quantitated in moderately affected rats intoxicated with HD at three daily dosing rates (175, 250, and 400 mg/kg/day)."( gamma-diketone peripheral neuropathy. II. Neurofilament subunit content.
Chiu, FC; He, DK; Lehning, EJ; LoPachin, RM; Opanashuk, LA, 2000
)
0.31
" To investigate the mechanism of diminished NF content, subunit (NF-L, -M and -H) gene expression was quantified in dorsal root ganglion (DRG) of slightly affected and moderately intoxicated groups of rats exposed to 2,5-hexanedione (HD) at one of three daily dosing rates (175, 250 and 400 mg/kg per day)."( Gamma-diketone peripheral neuropathy III. Neurofilament gene expression.
He, DK; Lehning, EJ; LoPachin, RM; Opanashuk, LA, 2001
)
0.5
" To evaluate this possibility, groups of rats were exposed to HD at dosing schedules (175 mg/kg x 101 days or 400 mg/kg x 26 days) that produced moderate levels of neurological deficits and prevalent axon atrophy in spinal cord white matter tracts."( 2,5-Hexanedione-induced changes in the monomeric neurofilament protein content of rat spinal cord fractions.
He, D; LoPachin, RM; Opanashuk, LA; Reid, ML, 2004
)
1.77
" To determine the effects of HD on the stationary and mobile NF pools, groups of rats were exposed to HD at dosing schedules (175 mg/kg x 101 days or 400 mg/kg x 26 days) that produced moderate levels of neurological deficits and, as assessed by previous studies, prevalent axon atrophy in peripheral nerve."( 2,5-Hexanedione-induced changes in the neurofilament subunit pools of rat peripheral nerve.
He, D; LoPachin, RM; Reid, ML, 2005
)
1.77
" HD was administrated to Wistar rats by intraperitoneal injection at dosage of 200 or 400 mg/kg/day (five-times per week)."( 2,5-Hexanedione induced decrease in cytoskeletal proteins of rat sciatic-tibial nerve.
Han, X; Xie, K; Yu, L; Zhang, C; Zhang, T; Zhao, X; Zhu, Z, 2005
)
1.77
" The above changes of gene expression were detectable within a short period after the dosing prior to the appearance of obvious pathological changes."( Effects of male reproductive toxicants on gene expression in rat testes.
Fukushima, T; Hamada, Y; Horii, I; Kikkawa, R; Komiyama, M; Mori, C; Yamamoto, T, 2005
)
0.33
"To investigate the mechanisms of the axonopathy induced by 2,5-hexanedione (2,5-HD), male Wistar rats were administered at a dosage of 400 mg/kg/day 2,5-HD (five times per week)."( Time-dependent alteration of cytoskeletal proteins in cerebral cortex of rat during 2,5-hexanedione-induced neuropathy.
Song, F; Xie, K; Yu, L; Yu, S; Zhang, C; Zhao, X, 2007
)
0.81
" Male adult Wistar rats were administered by intraperitoneal injection at a dosage of 200 or 400 mg/kg HD, five days per week for 8 weeks."( Expression of Bcl-2, Bax and Caspase-3 in nerve tissues of rats chronically exposed to 2,5-hexanedione.
Cui, N; Li, S; Xie, K; Yu, L; Zhang, C; Zhang, T; Zhao, X; Zhu, Z, 2007
)
0.56
" The present study investigates dose-response relationships for these classic Sertoli cell toxicants using histopathology endpoints."( Dose-dependent effects of sertoli cell toxicants 2,5-hexanedione, carbendazim, and mono-(2-ethylhexyl) phthalate in adult rat testis.
Boekelheide, K; Bryant, BH; Hall, SJ; Moffit, JS, 2007
)
0.59
"To investigate the reversibility of the neuropathy induced by 2,5-HD, adult male rats were administered at a dosage of 400 mg/kg/day 2,5-HD (five times per week) for 2, 4, and 8 weeks, respectively."( The reversibility of neurofilaments decline induced by 2,5-hexanedione in rat nerve tissues.
Song, F; Wang, Q; Xie, K; Yu, S; Zhang, C; Zhou, G, 2008
)
0.59
"To investigate the mechanisms and biomarker of the neuropathy induced by 2,5-hexanedione (HD), male Wistar rats were administrated HD at dosage of 200 or 400mg/kg for 8 weeks (five-times per week)."( Changes of cytoskeletal proteins in nerve tissues and serum of rats treated with 2,5-hexanedione.
Hou, LY; Song, FY; Wang, QS; Xie, KQ; Zhang, CL, 2008
)
0.8
"Male Wistar rats were administered at a dosage of 400 mg/kg/day 2, 5-HD for 2, 4 and 8 weeks respectively."( [Dynamic study of neurofilament contents in rat's spinal cord induced by 2, 5-hexanedione].
Song, FY; Wang, QS; Xie, KQ; Yu, LH; Zeng, T; Zhu, ZP, 2008
)
0.35
" To investigate the change of NFs degradation and their possible role in n-hexane neuropathy, adult male Wistar rats were administered intraperitoneally at a dosage of 400 mg/kg/day 2,5-hexanedione (2,5-HD) for 4 weeks."( 2,5-hexanedione altered the degradation of low-molecular-weight neurofilament in rat nerve tissues.
Gao, Y; Kou, R; Song, F; Xie, K; Zhang, Q; Zou, C, 2012
)
2.01
"Dose-dependent effects were observed between the dosage of n-hexane and 2, 5-hexanedione, and pyrrole adducts in tissues."( Correlation between levels of 2, 5-hexanedione and pyrrole adducts in tissues of rats exposure to n-hexane for 5-days.
Guo, Y; Xie, K; Yin, H; Zeng, T; Zhao, X, 2013
)
0.39
" Dose-response studies using adult male Fischer 344 rats subchronically exposed to model Sertoli cell toxicants (0."( From the Cover: Sperm Molecular Biomarkers Are Sensitive Indicators of Testicular Injury following Subchronic Model Toxicant Exposure.
Anderson, LM; Boekelheide, K; Dere, E; Wilson, SK, 2016
)
0.43
" Results showed that the increased pyrrole adducts in hair, urine and serum accumulated in dose-response relationship."( Hair pyrrole adducts serve as biomarkers for peripheral nerve impairment induced by 2,5-hexanedione and n-hexane in rats.
Li, M; Li, X; Wang, Q; Wang, S; Xie, K; Zhang, C, 2018
)
0.71
"Nine-week old SPF male Wistar rats were administered at daily dosing of 100 and 300 mg/kg by intraperitoneal injection for continuous 8 weeks(five times every week)."( [Effects of 2, 5-hexanedione on S100β of Schwann cells in rat sciatic nerves].
Cheng, D; Guo, J; Li, H; Yan, Y; Yang, F; Yao, W; Zhang, T; Zhou, W, 2020
)
0.56
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
human xenobiotic metaboliteAny human metabolite produced by metabolism of a xenobiotic compound in humans.
neurotoxinA poison that interferes with the functions of the nervous system.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
diketoneA compound that contains two ketone functionalities.
methyl ketoneA ketone of formula RC(=O)CH3 (R =/= H).
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (9)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASEHomo sapiens (human)Potency0.05620.003245.467312,589.2998AID2517
RAR-related orphan receptor gammaMus musculus (house mouse)Potency3.58800.006038.004119,952.5996AID1159521; AID1159523
aldehyde dehydrogenase 1 family, member A1Homo sapiens (human)Potency22.38720.011212.4002100.0000AID1030
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency35.28720.003041.611522,387.1992AID1159552
retinoid X nuclear receptor alphaHomo sapiens (human)Potency22.46780.000817.505159.3239AID1159527
67.9K proteinVaccinia virusPotency8.80060.00018.4406100.0000AID720579; AID720580
thyroid stimulating hormone receptorHomo sapiens (human)Potency55.92640.001628.015177.1139AID1259385
Nuclear receptor ROR-gammaHomo sapiens (human)Potency0.37580.026622.448266.8242AID651802
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
ORF73Human gammaherpesvirus 8EC50 (µMol)75.00000.06008.134632.1400AID435023
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (13)

Processvia Protein(s)Taxonomy
negative regulation of transcription by RNA polymerase IINuclear receptor ROR-gammaHomo sapiens (human)
xenobiotic metabolic processNuclear receptor ROR-gammaHomo sapiens (human)
regulation of glucose metabolic processNuclear receptor ROR-gammaHomo sapiens (human)
regulation of steroid metabolic processNuclear receptor ROR-gammaHomo sapiens (human)
intracellular receptor signaling pathwayNuclear receptor ROR-gammaHomo sapiens (human)
circadian regulation of gene expressionNuclear receptor ROR-gammaHomo sapiens (human)
cellular response to sterolNuclear receptor ROR-gammaHomo sapiens (human)
positive regulation of circadian rhythmNuclear receptor ROR-gammaHomo sapiens (human)
regulation of fat cell differentiationNuclear receptor ROR-gammaHomo sapiens (human)
positive regulation of DNA-templated transcriptionNuclear receptor ROR-gammaHomo sapiens (human)
adipose tissue developmentNuclear receptor ROR-gammaHomo sapiens (human)
T-helper 17 cell differentiationNuclear receptor ROR-gammaHomo sapiens (human)
regulation of transcription by RNA polymerase IINuclear receptor ROR-gammaHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (10)

Processvia Protein(s)Taxonomy
RNA polymerase II cis-regulatory region sequence-specific DNA bindingNuclear receptor ROR-gammaHomo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificNuclear receptor ROR-gammaHomo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificNuclear receptor ROR-gammaHomo sapiens (human)
DNA-binding transcription factor activityNuclear receptor ROR-gammaHomo sapiens (human)
protein bindingNuclear receptor ROR-gammaHomo sapiens (human)
oxysterol bindingNuclear receptor ROR-gammaHomo sapiens (human)
zinc ion bindingNuclear receptor ROR-gammaHomo sapiens (human)
ligand-activated transcription factor activityNuclear receptor ROR-gammaHomo sapiens (human)
sequence-specific double-stranded DNA bindingNuclear receptor ROR-gammaHomo sapiens (human)
nuclear receptor activityNuclear receptor ROR-gammaHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (4)

Processvia Protein(s)Taxonomy
nucleusNuclear receptor ROR-gammaHomo sapiens (human)
nucleoplasmNuclear receptor ROR-gammaHomo sapiens (human)
nuclear bodyNuclear receptor ROR-gammaHomo sapiens (human)
chromatinNuclear receptor ROR-gammaHomo sapiens (human)
nucleusNuclear receptor ROR-gammaHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (13)

Assay IDTitleYearJournalArticle
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (416)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990132 (31.73)18.7374
1990's132 (31.73)18.2507
2000's79 (18.99)29.6817
2010's59 (14.18)24.3611
2020's14 (3.37)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 39.91

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index39.91 (24.57)
Research Supply Index6.13 (2.92)
Research Growth Index4.39 (4.65)
Search Engine Demand Index59.70 (26.88)
Search Engine Supply Index1.98 (0.95)

This Compound (39.91)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials3 (0.66%)5.53%
Reviews17 (3.72%)6.00%
Case Studies1 (0.22%)4.05%
Observational0 (0.00%)0.25%
Other436 (95.40%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]